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Abstract
Hundreds of different human skeletal disorders have been characterized at molecular level and a growing number of
resembling dysplasias with orthologous genetic defects are being reported in dogs. This study describes a novel genetic
defect in the Brazilian Terrier breed causing a congenital skeletal dysplasia. Affected puppies presented severe skeletal
deformities observable within the first month of life. Clinical characterization using radiographic and histological methods
identified delayed ossification and spondyloepiphyseal dysplasia. Pedigree analysis suggested an autosomal recessive
disorder, and we performed a genome-wide association study to map the disease locus using Illumina’s 22K SNP chip arrays
in seven cases and eleven controls. A single association was observed near the centromeric end of chromosome 6 with a
genome-wide significance after permutation (pgenome = 0.033). The affected dogs shared a 13-Mb homozygous region
including over 200 genes. A targeted next-generation sequencing of the entire locus revealed a fully segregating missense
mutation (c.866C.T) causing a pathogenic p.P289L change in a conserved functional domain of b-glucuronidase (GUSB).
The mutation was confirmed in a population of 202 Brazilian terriers (p = 7,71610229). GUSB defects cause
mucopolysaccharidosis VII (MPS VII) in several species and define the skeletal syndrome in Brazilian Terriers. Our results
provide new information about the correlation of the GUSB genotype to phenotype and establish a novel canine model for
MPS VII. Currently, MPS VII lacks an efficient treatment and this model could be utilized for the development and validation
of therapeutic methods for better treatment of MPS VII patients. Finally, since almost one third of the Brazilian terrier
population carries the mutation, breeders will benefit from a genetic test to eradicate the detrimental disease from the
breed.
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Introduction
Genetic disorders with significant involvement of the skeletal
system form a group of clinically and genetically heterogeneous
diseases arising through abnormalities in the development, growth
or maintenance of skeletal structures. Over 450 skeletal conditions
have been recognized in human with variable etiologies,
challenging the diagnosis of the diseases [1]. Most of the skeletal
disorders are monogenic and can be classified based on their
clinical, radiographic, molecular and biochemical features.
The main component of bone and other connective tissues is
extracellular matrix (ECM), which mainly consists of collagen and
proteoglycans. ECM has an essential role in skeletal development
which is proven by numerous amounts of skeletal disorders arising
through mutations in the genes encoding the structural proteins
like aggrecan, perlecan or several types of collagens causing
collagenopathies and osteogenesis imperfecta (OI) [1]. Skeletal
deformities are also a prominent feature in certain lysosomal
storage diseases (LSD) called mucopolysaccharidoses (MPS), in
which deficiencies of lysosomal enzymes involved in the degrada-
tion of glycosaminoglycan (GAG) chains of the proteoglycans
cause an accumulation of GAGs in lysosomes of many different
cell types, mainly in the connective tissue. Eleven different forms
(MPS I to IIIA,B,C and IV to IX) have been characterized in
human and categorized based on the underlying enzyme
deficiency [2]. Although clinical characteristics differ between
mucopolysaccharidoses and even within a particular MPS type,
they also share features such as dwarfism, undeveloped epiphyseal
centers, dysostosis multiplex, facial dysmorphia, corneal clouding
and organomegaly [2].
Dog is a unique species with extreme morphological variation.
Particular skeletal features have been intentionally selected in
many breeds and they have become fixed breed characteristics.
For example, the length of the legs varies massively across breeds.
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Short legs caused by chondrodysplasia are a distinguishable
feature in many breeds such as Dachshund or Basset Hound and
associate with an extra functional copy of Fgf4 gene [3]. Abnormal
growth of craniofacial bones leads to brachycephaly in Boxers,
Bulldogs and other short muzzled breeds. This trait was recently
mapped to chromosome 1 [4]. Besides extensive and benign
morphological variation among breeds, dogs have detrimental
skeletal disorders. For example, various forms of OI have been
characterized and linked to mutations in the COL1A1, COL1A2
and SERPINH1 genes [5–7].
Annotation of the canine genome and subsequent development
of genomic tools provides a unique approach to tackle the genetics
of skeletal disorders in a large animal model with a genetically
isolated population structure. Canine skeletal disorders resemble
human conditions and it is not surprising that most of the known
genes have been orthologues of the corresponding human
syndromes [3,5–8]. As a part of our ongoing canine genomics
projects, we have encountered Brazilian Terriers with severe
skeletal defects. Brazilian Terrier is a small smooth-coated native
Brazilian breed with a history descending from crosses of local
Brazilian small dogs with imported European terriers. The breed is
popular in its native country but almost unknown elsewhere except
in Finland, which has one of the largest populations outside Brazil
with ,150 annual registrations within the last five years.
We aimed here to describe the clinical and pathological features
of the skeletal disease in Brazilian Terriers and find its genetic
cause. Using a genome-wide association study we mapped the
disease to a ,13-Mb region of Canis lupus familiaris chromosome 6
(CFA6) and subsequent targeted next-generation sequencing
(NGS) identified a novel missense mutation in the affected puppies
in the b-glucuronidase (GUSB) gene, which causes MPS VII. Our
study establishes a new spontaneous canine model for human MPS
VII and enables the development of a genetic test to eradicate this
detrimental syndrome from the breed.
Results
Clinical Features Indicate Ambulatory Dand Dwarfism
A litter of seven Brazilian Terriers was presented to clinic
because three of the puppies showed multiple severe skeletal
defects at the age of 4 weeks. General clinical examination and
radiography was performed for the affected puppies and their
gender-matched healthy littermates and the healthy dam to
explore the cause for skeletal deformities. The affected puppies
showed normal behavioural activities and appetite but they were
unable to walk and function properly (Video S1). The congenital
and progressive signs became evident within the first four weeks of
life. All affected puppies presented similar phenotypic character-
istics with brachycephalic craniofacial morphology, dwarfism and
deformed legs with crooked radiocarpal joints and prominent joint
hyperlaxity especially in the hind limbs (Fig. 1A,C). Ophthalmo-
scopic examination revealed no pathological changes in the eyes.
The weights of the three affected puppies and four normal
littermates were measured at birth and followed until 3 weeks of
age. The affected puppies showed severe growth retardation and
had 35% less weight than their healthy littermates at the age of
three weeks (Fig. 1E). Later, several other related Brazilian
Terrier litters became available and altogether 15 affected dogs
from 8 different litters were confirmed to have similar clinical
signs, though, the severity of the phenotype varied even among the
affected littermates. Due to poor prognosis the affected puppies
were euthanized between 2 to 6 weeks of age except the two that
died spontaneously at the age of 1 and 3 weeks for unknown
reasons. Both sexes were equally affected.
Radiological Findings Reveal Spondyloepiphyseal
Dysplasia
Seven affected dogs and three age- and sex-matched controls
were radiographed to investigate the structural abnormalities. In
addition, radiographs were taken from the dam of the first litter.
Epiphyseal dysplasia of long bones and vertebral endplates with
delayed ossification of the epiphyseal cartilages was evident in all
affected dogs (Fig. 2A,C,E). Additionally, the maxilla was short
(prognathia inferior), the calvarium was widened, and the
ossification centers of the cuboid bones of carpus and tarsus were
reduced in size when compared to the normal littermates (Fig. 2A-
D). In the affected dogs skeletal radiopacity was generally slightly
decreased, but the cortices of the long bones appeared normal. All
affected individuals had also marked carpal and tarsal joint
effusion (Fig. 2A). The healthy littermates and the dam had no
skeletal changes.
Histopathological Findings Indicate Delayed Ossification
Postmortem tissues were collected from eight euthanized
puppies for histopathological analyses. During the post-mortem
necropsy, all the puppies were noted to have domed skulls and thin
and opaque skull bones. The long bones were soft and cortical
bone was thin. The carpal and tarsal bones were cartilaginous and
soft. The ligaments were soft and there was joint hyperlaxity.
Histological examination of the skeletal structures of the affected
puppies showed all structures of the growth plate, resting,
proliferating and hypertrophic layers of chondrocytes, in the long
bones (Fig. 2G). The secondary ossification centers in the
epiphyses were either small or completely lacking and occasionally
there were several separate spots of loose fibrous tissue without any
sign of osteogenesis (Fig. 2I). The carpal and tarsal bones were
composed mainly from cartilage. The ossification centers were
either lacking or small and included thin and irregular primary
trabeculae. The vertebral bodies had occasionally irregular
cartilage columns in the growth plate and inclusions of loose
fibrous tissue (Fig. 2J). No gross abnormalities in the other tissues
were found.
GWAS Maps the Disease to CFA6
A large pedigree tracing all the affected dogs back to a
common Brazilian ancestor was established (Fig. 3). Pedigree
analysis suggested an autosomal recessive mode of inheritance.
There were several affected puppies in each litter and all
parents were normal. Both males (n = 7) and females (n = 5)
were affected. The proportion of the affected dogs in the litters
was 31,6%, slightly over an average of 25% assumed for a
recessive condition.
We performed a genome wide association study (GWAS) to
map the disease locus with Illumina’s 22K canine SNP chips in a
cohort of 18 dogs including 7 cases and 11 controls. A case-control
association test revealed significant association on CFA6 with the
best SNP (BICF2G630808208) at 7,265, 846 Mb
(praw = 1,86610
25, pgenome = 0,03313) (Fig. 4A). Assessment of
genotypes at the CFA6 locus revealed a long shared homozygosity
block in the affected dogs spanning from 3, 341,099 bp to 16,
324,133 bp (Fig. 4B). In addition, all three obligate carriers
(parents of the affected dogs) were heterozygous for the haplotype.
The region is in the vicinity of the centromeric end of the CFA6
challenging the exact definition of the beginning of the homozy-
gous block. Homozygous block contained 137 SNPs of which none
showed a complete segregation between cases obligate carriers and
other controls (Fig. 4B).
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Figure 1. Morphological features of the affected Brazilian Terriers. Deformed legs with crooked radiocarpal joints and prominent joint
hyperlaxity especially in the hind limbs (A) and a brachycephalic craniofacial morphology (C) presented by a 4-week-old Brazilian Terrier puppy
compared to a healthy littermate (B,D). The affected puppies (n = 3) were severely growth retarded and weighted 35% less than their healthy
littermates (n = 4) at the age of three weeks (E).
doi:10.1371/journal.pone.0040281.g001
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Next Generation Sequencing Identifies a Missense
Mutation in GUSB
The associated homozygous region contains at least 210
annotated or predicted genes (Fig. 4B) including several genes
with possible role in the bone formation. We selected two
candidate genes for further investigation, namely Procollagen C-
endopeptidase enhancer (PCOLCE) and SMAD ubiquitin regulatory factor
1 (Smurf1). PCOLCE binds specifically to the type I procollagen
C propeptide and has a role in collagen maturation [9], a
process in which defects have been linked to several skeletal
disorders. Smurf1 has an essential role in the regulation of
osteoblast differentiation [10,11]. We sequenced all exons,
except the first exon of Smurf1 gene, in both genes including
exon-intron boundaries and splice sites and 59- and 39-UTRs
from two affected puppies and two obligate disease carriers. We
did not find any segregating coding variant in either of the
genes.
Due to a large number of genes in the genomic region we
decided to proceed with a next generation sequencing approach.
The entire 13-Mb associated region was captured from two cases
and two controls with opposite haplotypes (Fig. 4B) using
NimbleGen’s in-solution capture method followed by a paired-
end NGS by HiSeq2000. We found altogether ,13000-19000
SNPs and ,5000 indels in each dog (Table 1). The variant lists
between cases and controls were then compared to discover
possible disease-causing variants. Besides the two Brazilian
Terrier controls we used 32 additional healthy dogs from four
different breeds as controls to filter out common variants. We
found two novel homozygous exonic SNPs, one deletion and one
Figure 2. Radiographic and histological features of skeletal disease in Brazilian Terrier puppies. Comparison of the hind limbs of an
affected 4-week-old puppy (A) and a healthy littermate (B) revealed epiphyseal dysplasia in the affected dog. The ossification centers of the epiphyses
of the proximal tibia (long arrow) and tarsal bones (short arrow) are smaller in the affected puppy while the epiphyses of the healthy littermate are
normally mineralized. The vertebral endplates of the lumbar spine (arrow) are poorly mineralized in the affected (C) puppy as compared with the
healthy littermate (D). The skull of an affected 6-week-old Brazilian Terrier (E) has brachycephalic appearance with shortened maxilla. Radiopacity of
the bones is reduced. The cervical vertebral endplates are not mineralized (arrow). A skull of a normal littermate is shown in comparison (F).
Histological examination of the skeletal structures of a 4-week-old affected puppy showed normal growth plate with resting, proliferating and
hypertrophic layers of chondrocytes in the tibia (G) but lack of secondary ossification center and occasional separate spots of loose fibrous tissue
without sign of osteogenesis (I). The lack of secondary ossification centers and irregularities of the growth plate were present in the vertebral bodies
(J). The epiphysis of a 5-week old healthy puppy is shown in comparison (H). Scale bar 100 mm.
doi:10.1371/journal.pone.0040281.g002
Figure 3. An example of our large Brazilian Terrier pedigree established around the affected puppies. The pedigree with multiple
affected dogs in the litters, equal gender distribution and healthy parents suggests a recessive mode of inheritance. Squares note males and circles
females. Black-filling indicates affected dogs. Genotypes of the GUSB gene (T/T = homozygous mutation allele, C/C =homozygous wild type allele) are
shown below the boxes. Dogs used in the NGS are marked by asterisks.
doi:10.1371/journal.pone.0040281.g003
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insertion unique for cases. The 9-bp deletion was located in
monoacylglycerol O-acyltransferase 3 (MOGAT3) gene (at position
BROADD2:6:11681043) which is an intestinal specific enzyme
implicated in fat absorption [12]. The 3-bp insertion was located
in olfactory receptor, family 2, subfamily AE, member 1 (OR2AE1) gene
(at position BROADD2:6:12694743). Neither of these genes were
potential candidate genes for the studied disease due to their
known restricted function outside the skeletal system. One of the
exonic SNPs was synonymous and the other non-synonymous.
The non-synonymous exonic variant was found in the exon 5
(c.866C.T) of the b-glucuronidase (GUSB) gene, resulting in a
proline to leucine substitution at amino acid position 289
(p.P289L).
The GUSB enzyme is a lysosomal homotetramer [13]. The
human and canine monomers consist of 651 amino acids and
human protein includes three functional domains comprised of
residues 22–223, 224–342 and 343–632. The canine GUSB is
81% similar to human GUSB at amino acid level [8]. The first
domain of the GUSB monomer forms a distorted barrel-like
structure with a jelly roll motif and two b-hairpin loops. The
second domain is similar to the immunoglobulin constant domains
and the third forms the active enzyme site with a/b- or TIM-
barrel motif [14]. The identified p.P289L substitution of GUSB in
the affected Brazilian Terriers resides in the middle of the second
domain. A multiple alignment of this affected domain across
eukaryotic and prokaryotic species revealed that the substitution
site and its surrounding residues are well conserved (Fig. 5). The
disruption of the conserved region by the substitution is likely to
impair the GUSB structure and function, which was further
supported by a PolyPhen-2 software predicting a ‘‘probably
damaging’’ effect of the mutation with a maximum score 1.0.
For the validation of the c.866C.T variant as a causative
mutation segregating with the disease we genotyped a set of 202
Brazilian Terriers available from our canine DNA bank including
15 cases, 12 obligatory carriers and 175 healthy controls. Among
the 187 healthy dogs, 134 dogs were homozygous for the wild type
allele and 53 dogs were heterozygous for the c.866C.T variant.
All affected dogs were homozygous and all obligatory carriers
heterozygous for the variant. The results confirmed a significant
association of the c.866C.T variant with the disease
(p = 7,71610229). The carrier frequency among the healthy
population was 28,3%. We sequenced an additional panel of
166 dogs from 36 different breeds to further strengthen the
causality of the mutation. None of the additional dogs carried the
mutation. Collectively, these results validate the disease locus
identified through GWAS and indicate the full segregation of the
mutation with the recessive disease.
The Affected Dogs have Elevated Urinary GAGs and
Substantially Decreased b-glucuronidase Activity
Deficient b-glucuronidase activity leads to an elevation of GAGs
in urine and therefore the quantitative measurement of urinary
GAGs are commonly used in screening patients for mucopolysac-
charidosis. We performed a colorimetric quantification of urinary
GAGs from three affected puppies (,6 weeks of age) and three
healthy age-and breed-matched controls to investigate the
functional effect of the mutation. All the affected dogs were
genotyped homozygous for the mutation and controls for wild type
allele. The total urinary GAGs were measured biochemically in
relation to creatinine levels. We found an average of 2.7-fold
increase in GAGs in the affected dogs (Table S2). In addition, we
determined the activity of b-glucuronidase in the serum of the
three affected dogs and six control dogs from which three were
heterozygous for the mutation (carrier) and three were homozy-
gous for the wild type allele (normal). In the affected dogs, the
enzyme activity was severely impaired with a mean residual
activity of 0,2% compared with the wild type dogs (Table 2). The
GUSB activity in the carrier dogs was also reduced to 67% further
supporting the detrimental effect of the mutation for the GUSB
function. The activity of another lysosomal enzyme, a-mannosi-
dase, was within the control range, although much more
variability was observed in the study cohort. GUSB has been
shown to be stable in the serum upon storage while a-mannosidase
and several other lysosomal enzymes are more unstable which
might explain the more wide range in the measured activity [15].
These results confirm the predicted pathogenic effect of the GUSB
Figure 4. A genome-wide association study reveals an associated locus at CFA6. Manhattan plot indicates the best SNP with a raw and an
empirical p-value after 100 000 permutations (A). Affected dogs share a 13-Mb homozygous haplotype, which contains over 200 genes (B). Colors in
haplotype block are as follows: plum marks the homozygous allele, orange heterozygous allele and yellow an opposite homozygous allele. Dogs used
for the NGS are marked by asterisks. A targeted sequencing of the entire locus identified a homozygous c.866C.T mutation in the exon 5 of the
GUSB gene (C). The mutation was found by next generation sequencing (D) and was validated by Sanger sequencing (E).
doi:10.1371/journal.pone.0040281.g004
Table 1. SNP and indel statistics of the NGS of the identified locus in Brazilian Terriers.
Sample No of reads %mapped Coverage Total no of variants
No of variants in coding
regions
SNPs Indels SNPs Indels
Control 1 6303701 99.90 48 20555 6214 578 28
2 6776456 99.92 52 19530 6240 640 23
Case 3 6834323 99.86 52 13044 4781 549 27
4 7060250 99.91 54 12742 4505 558 28
Case-specific All variants 410 154 10 3
Novel homozygous variants 291 52 2 2
The 13,2-Mb locus at CFA6 was captured and sequenced in two cases and two controls with opposite haplotypes. Variants were discovered by comparing the target
sequence with the reference sequence. Ensembl’s CanFam2.0 was used as a reference. The variants present only in the affected dogs were found by comparing the two
Brazilian Terriers cases with the two breed controls and 32 other dogs from four breeds without any skeletal diseases.
doi:10.1371/journal.pone.0040281.t001
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mutation and demonstrate the disease in Brazilian Terriers to be
MPS VII.
Discussion
This study characterizes a severe developmental disorder in
Brazilian Terriers and identifies its genetic cause. The affected
dogs suffer from multiple skeletal defects, growth retardation and
they have failure to thrive leading to a premature death or
euthanasia within the first weeks of life. Pathological and
radiological studies revealed a prominent spondyloepiphyseal
dysplasia due to a delayed ossification. The genetic cause of the
recessive disease was mapped to CFA6 resulting in the identifi-
cation of the causative mutation in the GUSB gene. The GUSB
mutation defines this canine skeletal syndrome as a mucopolysac-
charidosis VII, a lysosomal storage disease affecting mainly
connective tissue.
The GUSB gene encodes a lysosomal b-glucuronidase that
degrades GAGs, including heparan sulfate, dermatan sulfate, and
chondroitin-4,6-sulfate. Deficient b-glucuronidase activity causes
MPS VII (Sly syndrome) [16]. GUSB mutations have been
described in many species including human, mouse, cat and
dog. Typical features in human patients (OMIM #253220)
include mental retardation, skeletal deformities, corneal clouding
and hepatosplenomegaly. The clinical variability among human is
extensive ranging from a prenatal lethality to mild skeletal
abnormalities with normal intelligence. Almost 50 unique muta-
tions have been described in human. The site of the mutation in
the GUSB gene correlates with the residual enzymatic activity and
related clinical severity [17]. Only a small percentage of normal
GUSB activity (2–3%) can protect against a severe phenotype.
Besides human, seven spontaneous or induced murine MPS VII
models have been reported [18–22]. All models present similar
clinical, morphological and histopathological characteristics but
the severity of the clinical signs depends on the strain. The
phenotypical features in mice are comparable with human MPS
VII patients including shortened life span, dysmorphic facial
features, skeletal dysplasia and widespread lysosomal storage of
GAGs in various tissues.
Feline GUSB deficiency has been described in three separate
cases but the causative mutation has been identified only in one of
them [23–25]. All feline models share clinical similarities including
a young age of onset, dwarfism, facial dysmorphism, walking
difficulties, corneal clouding, epiphyseal dysplasia of the vertebra
and long bones, and vacuoles in several tissues. The causative
Figure 5. The conservation of the GUSBmutation site. A multiple alignment of the substitution site (P289) indicates a high conservation across
taxa including eukaryotic and prokaryotic species. The p.P289L mutation is predicted to be pathogenic and likely disrupts the structure of the GUSB
enzyme.
doi:10.1371/journal.pone.0040281.g005
Table 2. Lysosomal enzyme activities in the serum of affected
and healthy Brazilian Terriers.
Range (n)
Enzyme Affected Carrier Normal
b-glucuronidase 0,05–0,31 (3) 72,4–102,6 (3) 85,7–151,1 (3)
a-mannosidase 802,7–833,1 (3) 1190,7–2078 (3) 560,6–2624,9 (3)
The activity of b-glucuronidase and a-mannosidase was measured from the
serum samples of three affected, carrier and normal dogs. Activity is expressed
as mmol/l/h.
doi:10.1371/journal.pone.0040281.t002
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mutation, p.E351K, in one population of cats affects a highly
conserved residue [25].
Canine MPS VII have been previously identified in two cases, a
mixed breed dog and a German Shepherd [26,27]. The first
clinical signs in these dogs appeared at 2 to 5 months of age and
involved weakness of the hind legs followed by a progressive
dysfunction of all limbs. The affected dogs presented also other
typical MPS VII features including growth retardation, facial and
other skeletal dysmorphisms, and corneal clouding. Joints were
extremely lax and easily subluxated and radiographic examination
showed severe epiphyseal dysplasia. Abnormalities in several other
organs were also present including hepatomegaly, tracheal
dysplasia and cardiac abnormalities. MPS VII was caused in both
cases by the p.R166H substitution resulting in a severe reduction
of the GUSB enzymatic activity [8,27].
We described a novel canine GUSB mutation, p.P289L, in
Brazilian Terriers with a more severe skeletal phenotype. The
affected puppies had a prominent limb dysfunction and they were
never able to ambulate properly. However, unlike the previous
canine models, Brazilian Terriers did not have corneal clouding or
detectable abnormalities in other organs. This could be explained
by the young age (,4 weeks) of the affected dogs at the time of
euthanasia. For example, corneal opacity became evident in the
other canine models at 8 weeks of age and in cats at few months of
age [24–26]. As it is known that the gradual accumulation of
undegraded GAGs in the lysosomes correlates with the progressive
nature of the disease, in most human and animal models the
clinical signs appear gradually. Regardless of the differences, most
features in Brazilian Terriers were similar to the other canine,
feline, murine and human MPS VII, including growth retardation,
craniofacial dysmorphisms, excessive joint laxity and epiphyseal
dysplasia with the involvement of the long bones and vertebral end
plates. The earlier onset of the disease in Brazilian Terriers
compared to the other canine and feline models suggests that the
mutation is highly detrimental for the GUSB enzymatic activity.
The p.P289L mutation affects a conserved site of the second
functional immunoglobulin-like domain in GUSB and thus, likely
alters GUSB structure or function. Indeed, the determination of
the b-glucuronidase activity in the serum of affected puppies
showed that the residual activity was near absent (0,2%) and was
also reduced in the carrier dogs confirming the pathogenic nature
of the p.P289L mutation. Defective enzymatic activity of GUSB
leads to elevated secretion of GAGs into urine and the affected
puppies in this study had threefold elevation in urinary GAGs.
Our clinical, genetic and biochemical data confirms the disease as
MPS VII.
In summary, we describe a severe canine skeletal disease and
identify a syndrome-defining mutation in the GUSB gene. This
study provides new information about genotype-phenotype
correlation in a very early form of the disease and establishes a
novel canine model for MSP VII. In general, there are two
primary treatment options, enzyme replacement therapy (ERT) or
hematopoietic stem cell transplantation (HSCT) that can provide
substantial benefits in MPSs in human patients [28]. For example,
MPS I (Hurler disease) patients are successfully treated by both
ERT and HSCT [29–33]. Currently, there is not an efficient
treatment for MPS VII. Gene therapy has been successfully
performed in dogs using retroviral vectors expressing canine
GUSB [34]. Our canine patients could be utilized for the
development and validation of such therapies, which could
eventually be advantageous for both dogs and human. Meanwhile,
we have developed a genetic test to eradicate the disease from the
breed, in which almost every third dog carries the mutation.
Materials and Methods
Study Cohort
The research group was contacted by breeders about an
unknown debilitating skeletal dysplasia in Brazilian Terrier
puppies. To investigate the clinical and genetic characteristics of
the disease a breed-wide collection was initiated to sample both
affected and control dogs. EDTA-blood samples were collected
altogether from 202 privately owned Brazilian Terriers including
15 affected puppies and 187 healthy controls. The affected animals
came from eight different litters with the average age of the onset
of the clinical signs being 3 weeks. A large pedigree was established
around the affected dogs using the GenoPro genealogy software
(http://www.genopro.com/) and utilizing the public dog registry
by the Finnish Kennel Club (http://jalostus.kennelliitto.fi) to
evaluate the mode of inheritance (Fig. 3). Blood samples were
stored at 220uC until genomic DNA was extracted using the
Puregene DNA Purification Kit (Gentra Systems). DNA concen-
tration was determined with the ND-1000 UV/Vis Spectropho-
tometer (NanoDrop Technologies). Collection of blood samples
was approved by the Animal Ethics Committee at the State
Provincial Office of Southern Finland (ESLH-2009-07827/Ym-
23).
Radiological and Histological Studies
Seven affected puppies, a dam and three healthy littermates
from five different litters were radiographically examined to study
the structural abnormalities. A laterolateral radiograph of the
whole body and laterolateral as well as ventrodorsal radiographs of
the skull were obtained. Affected and healthy puppies were
photographed and video recorded. Ophthalmoscopic examination
was performed for the three affected puppies by a board-certified
veterinary ophthalmologist. General post mortem examination
was performed for three affected puppies from the same litter.
Autopsies were taken from different tissues including lung, kidney,
spleen, heart, pituitary gland, brain, eye, long and short bones of
the limbs and spine. We performed histological analyses from
tissue samples (limb bones, spine, skull and mandible with teeth)
for four additional affected puppies to further explore the
microscopic changes during osteogenesis. We used a Brazilian
Terrier puppy without the skeletal disease but that had died due to
intestinal infection at 5 weeks of age as a control dog in the
histochemical analyses. Tissue samples were fixed in 10% formalin
for 48 hours, decalcified in Morse’s solution or in 10% EDTA,
dehydrated and embedded in paraffin. Paraffin blocks were cut in
to 5mm sections and stained with hematoxylin and eosin.
Genome Wide Association Study
Seven affected dogs from four nuclear families and eleven
control dogs (Fig. 3) were genotyped using Illumina’s Cani-
neSNP20 BeadChip of 22,362 validated SNPs. Healthy control
dogs included three obligate disease carriers (parents), two non-
affected siblings and six other related healthy dogs. The genotype
data was filtered with a SNP call rate of .95%, array call rate of
.95% and minor allele frequency of.5%. Based on these criteria
366 SNPs were removed for low genotyping efficiency and 5647
SNPs for low minor allele frequency. No individual dogs were
removed for low genotyping and no SNPs were removed because
of significant deviations from the Hardy-Weinberg equilibrium
(p,=0.0001). After frequency and genotyping pruning, 16595
SNPs remained for analyses. Basic case-control association test was
performed by PLINK [35]. Genome-wide significance was
ascertained with phenotype permutation testing (n=100,000).
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Mutation Screening and SNP Validation
Mutation screening of exons of Smurf1 and PCOLCE genes
including exon-intron junctions and 59- and 39 -UTRs was
performed using two clinically and patholocigally confirmed cases
and two obligate disease carriers. Primers were designed for exon 5
of the GUSB gene to validate the c.866C.T variant and PCR was
performed for 202 Brazilian Terriers including 15 affected dogs,
12 obligatory carriers and 175 additional healthy dogs. In
addition, a panel of 166 dogs from 36 different breeds was
genotyped for the variant (Table S1). Primer sequences are
available upon request. PCR reactions were carried out in a total
reaction volume of 20 ml with 20 ng of genomic DNA using a
standard PCR protocol. PCR products were purified with
ExoSAP-IT (GE Healthcare) and sequenced with a 37306l
DNA Analyzer (Applied Biosystems) and analyzed using Variant
Reporter v1.0 (Applied Biosystems).
Web-based software PolyPhen-2 (genetics.bwh.harvard.edu/
pph2) [36] was applied to evaluate the pathogenic effect of the
mutation. The score range for PolyPhen-2 is from 0 to 1 with the
threshold ‘‘probably damaging’’ at 0.85.
Target Enrichment and Next Generation Sequencing
We performed a targeted sequence capture and next generation
sequencing to identify the disease-causing mutation. We used
NimbleGen’s in-solution capture technology to enrich a 13,2-Mb
target region (CFA6: 3,250,000-16,400,000) for sequencing
(Roche NimbleGen). Probes for the target region were designed
by Roche NibleGen (Roche NimbleGen, Madison, WI, USA). We
selected two Brazilian Terrier cases and controls with opposite
haplotypes for target enrichment and sequencing. The same
targeting experiment contained also samples from our other
targeting projects including 8 Border Terriers, 12 Duck Tolling
Retrievers, 8 Schipperkes and 4 White West Highland Terriers
and these samples were used as additional controls.
Three micrograms of genomic DNA was sheared using Covaris-
S2 focused sonicator using following (duty cycle 10%, intensity 5
and 200 cycles per burst). Subsequent end repair, A-tailing and
ligation were performed using NEBNextH DNA Sample Prep
Master Mix Set 1 (New England BioLabs, Ipswich, MA, USA) )
according to manufacturer’s protocol with following modifications:
(1) 1ml of the 25mM Illumina Index PE adapter oligo mix (from
primers 59-GATCGGAAGAGCACACGTCT-39 and 59-
ACACTCTTTCCCTACACGACGCTCTTCCGATCT-39) was
used in adapter ligation. (2) After each consecutive library
preparation step the libraries were purified with Agencourt
AMPure XP -beads (Beckman Coulter, Brea, CA, USA). The
volume of the beads was 1.8 times the volume of the reaction. (3)
15 ng of each ligated library was used for pre-capture PCR
amplification in 5 parallel reactions per library with 14 amplifi-
cation cycles. (4) The initialization step in the amplification was
2 minutes instead of 30 seconds and the denaturation step was
20 seconds instead of 30 seconds. (5) Illumina’s three primer
multiplexing scheme was replaced by a direct two primer
amplification using universal forward primer (AATGATACGGC-
GACCACCGAGATCTACACTCTTTCCCTACAC-
GACGCTCTTCCGATCT) and an index primer (CAAGCA-
GAAGACGGCATACGAGATXXXXXXGTGACTGGAGTT-
CAGACGTGTGCTCTTCCGATCT). The latter
oligonucleotide contained a sample specific 6 base pair index tag
where XXXXXX is presented. All primers and oligonucleotides
were custom ordered from Sigma Aldrich (St. Louis, MO, USA).
The solution based enrichment was performed according to the
manufacturer’s instructions with following modifications: hybrid-
ization enhancing oligonucleotides (PE-HE1 and PE-HE2) were
replaced with 59-CAAGCAGAAGACGGCATACGAGAT-39,
59-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-
39 and 59- AATGATACGGCGACCACCGAGATCTA-
CACTCTTTCCCTACACGACGCTCTTCCGATCT-39to en-
hance performance on indexed libraries. Prepared sample libraries
were sequenced using Illumina’s HiSeq 2000 sequencing platform
according to manufacturer’s instructions (PE 101 bp reads).
Sample preparation, target enrichment experiments and variant
calling pipeline analysis [37] was performed by the core facility,
Institute for Molecular Medicine Finland (FIMM, Technology
Centre, University of Helsinki, Helsinki, Finland). Canine genome
build CanFam2 was used as reference sequence. Further data
analysis was performed using open source R language and
environment (http://www.r-project.org) and ANNOVAR soft-
ware for annotation of the genetic variants [38].
Biochemical Studies
Urine samples were collected from three affected and three
healthy Brazilian Terrier puppies. Urinary GAG levels were
measured using a protocol for colorimetric quantification of GAGs
based on de Jong et al. [39]. The final values were expressed as
GAG/creatinine ratios. Serum samples were collected from three
affected and six control Brazilian Terriers including three
heterozygous carriers and three wild type dogs. The samples were
stored and shipped at 220uC to the laboratory of Oulu University
Hospital where the activity of b-glucuronidase and a-mannosidase
was determined according to the routine protocols.
Supporting Information
Video S1 Ambulatory defects presented by a MPS VII-
affected Brazilian Terrier puppy at 4 weeks of age.
(WMV)
Table S1 Summary of the GUSB genotypes at nucleotide
position 866 in 41 different breeds. The genotyping was
performed by Sanger sequencing for all the samples except 12
Nova Scotia Duck Tolling Retrievers, 4 West Highland White
Terriers, 8 Border Terriers and 8 Schipperkes for which the
genotypes were collected from the NGS data. Genotypes are
denoted as C/C=homozygous wild type allele, C/T=heterozy-
gous carrier, T/T=homozygous mutation allele.
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Table S2 Urinary GAG analysis in the affected Brazilian
Terriers and the healthy controls. The urinary GAG/
creatinine ratios for the three affected Brazilian Terrier puppies
indicate elevated excretion of GAGs in the urine as compared to
the controls from same breed and age.
(DOC)
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